MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levelsNo neurotoxicity or dose-limiting toxicities observedTwo out of nine patients showed early. | June 18, 2023
Medigene AG to present Phase I clinical data for MDG1011 with poster presentation at EBMT 2023 Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.